Retinoids in chemoprevention and differentiation therapy

Carcinogenesis

Volumn 21, Issue 7, 2000, Pages 1271-1279

  Hansen, Laura A ^c   Sigman, Caroline C ^a   Andreola, Fausto ^c   Ross, Sharon A ^b   Kelloff, Gary J ^a   De Luca, Luigi M ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; AROMATIC HYDROCARBON RECEPTOR; ARSENIC OXIDE; CYTOCHROME P450; RETINAL; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID; RETINOL; RETINOL PALMITATE; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; BREAST CANCER; CARCINOGENESIS; CELL DIFFERENTIATION; CHEMOPROPHYLAXIS; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; DIETARY INTAKE; EPITHELIUM CELL; GENE EXPRESSION REGULATION; HEAD AND NECK CANCER; HOMEOSTASIS; HUMAN; LIGAND BINDING; LIVER CANCER; NONHUMAN; OXIDATION; PHENOTYPE; PRIORITY JOURNAL; PROMYELOCYTE; REMISSION; REVIEW; SKIN CANCER; TRANSGENIC MOUSE;

EID: 0033924399     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/21.5.271     Document Type: Review

References (116)

1. Goodman, D.S. (1984) Plasma retinol binding protein. In Sporn, M.B., Roberts, A.B. and Goodman, D.S. (eds) The Retinoids. Academic Press, Orlando, FL, Vol. 2, pp. 41-88.
2. Blomhoff, R., Green, M.H., Berg, T. and Norum, K.R. (1990) Transport and storage of vitamin A. Science, 250, 399-404.
3. Blomhoff, R. (1994) Vitamin A in Health and Disease. Marcel Dekker, New York, NY.
4. Creek, K.E., Silverman-Jones, C.S. and De Luca, L.M. (1989) Comparison of the uptake and metabolism of retinol delivered to primary mouse keratinocytes either free or bound to rat serum retinol-binding protein. J. Invest. Dermatol., 92, 283-289.
5. Bavik, C.O., Busch, C. and Eriksson, U. (1992) Characterization of a plasma retinol-binding protein membrane receptor expressed in the retinal pigment epithelium. J. Biol. Chem., 267, 23035-23042.
6. Ong, D.E., Newcomer, M.E. and Chytil, F. (1994) Cellular retinoid-binding proteins. In Sporn, M.B., Roberts, A.B. and Goodman, D.S. (eds) The Retinoids: Biology, Chemistry and Medicine, 2nd Edn. Raven Press, New York, NY, pp. 303-304.
7. Napoli, J.L. (1993) Biosynthesis and metabolism of retinoic acid: roles of CRBP and CRABP in retinoic acid homeostasis. J. Nutr., 123, 362-366.
8. Napoli, J.L. (1996) Retinoic acid biosynthesis and metabolism. FASEB J., 10, 993-1001.
9. Blaner, W.S. and Olson, J.A. (1994) Retinol and retinoic acid metabolism. In Sporn, M.B., Roberts, A.B. and Goodman, D.S. (eds) The Retinoids: Biology, Chemistry and Medicine, 2nd Edn. Raven Press, New York, NY. pp. 229-255.
10. Fernandez-Salguero, P., Pineau, T., Hilbert, D.M., McPhail, T., Lee, S.S., Kimura, S., Nebert, D.W., Rudikoff, S., Ward, J.M. and Gonzalez, F.J. (1995) Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor [see comments]. Science, 268, 722-726.
11. Fernandez-Salguero, P., Pineau,T., Hilbert, D.M., McPhail, T., Lee, S.S., Kimura, S., Nebert, D.W., Rudikoff, S., Ward, J.M. and Gonzalez, F.J. (1995) Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science, 268, 722-726.
12. Andreola, F., Fernandez-Salguero, P.M., Chiantore, M.V., Petkovich, M.P., Gonzalez, F.J. and De Luca, L.M. (1997) Aryl hydrocarbon receptor knockout mice (AHR-/-) exhibit liver retinoid accumulation and reduced retinoic acid metabolism. Cancer Res., 57, 2835-2838.
13. White, J.A., Beckett-Jones, B., Guo, Y.D., Dilworth, F.J., Bonasoro, J., Jones, G. and Petkovich, M. (1997) cDNA cloning of human retinoic acid-metabolizing enzyme (hP450RAI) identifies a novel family of cytochromes P450. J. Biol. Chem., 272, 18538-18541.
14. Fujii, H., Sato, T., Kaneko, S., Gotoh, O., Fujii-Kuriyama, Y., Osawa, K., Kato, S. and Hamada, H. (1997) Metabolic inactivation of retinoic acid by a novel P450 differentially expressed in developing mouse embryos. EMBO J., 16, 4163-4173.
15. Nagy, L., Saydak, M., Shipley, N., Lu, S., Basilion J.P., Yan, Z.H., Syka, P., Chandraratna, R.A., Stein, J.P., Heyman, R.A. and Davies, P.J. (1996) Identification and characterization of a versatile retinoid response element (retinoic acid receptor response element-retinoid X receptor response element) in the mouse tissue transglutaminase gene promoter. J. Biol. Chem., 271, 4355-4365.
16. Zaher, H., Fernandez-Salguero, P.M., Letterio, J., Sheikh, M.S., Fornace, A.J. Jr, Roberts, A.B. and Gonzalez, F.J. (1998) The involvement of aryl hydrocarbon receptor in the activation of transforming growth factor-beta and apoptosis. Mol. Pharmacol., 54, 313-321.
17. Wolbach, S.B. and Howe, P.R. (1925) Tissue changes following deprivation of fat-soluble A-vitamin. J. Exp. Med., 42, 753-778.
18. Sporn, M.B., Dunlop, N.M., Newton, D.L. and Smith, J.M. (1976) Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed. Proc., 35, 1332-1338.
19. Lancillotti, F., Darwiche, N., Celli, G. and De Luca, L.M. (1992) Retinoid status and the control of keratin expression and adhesion during the histogenesis of squamous metaplasia of tracheal epithelium. Cancer Res., 22, 6144-6152.
20. De Luca, L.M., Kosa, K. and Andreola, F. (1997) The role of vitamin A in differentiation and skin carcinogenesis. J. Nutr. Biochem., 8, 426-437.
21. Darwiche, N., Celli, G., Sly, L., Lancillotti, F. and De Luca, L.M. (1993) Retinoid status controls the appearance of reserve cells and keratin expression in mouse cervical epithelium. Cancer Res., 53, 2287-2299.
22. Genta, V.M., Kaufman, D.G., Harris, C.C., Smith, J.M., Sporn, M.B. and Saffiotti, U. (1974) Vitamin A deficiency enhances binding of benzo(a)pyrene to tracheal epithelial DNA. Nature, 247, 48-49.
23. Huang, F.L., Lancillotti, F. and De Luca, L.M. (1991) Retinoids in differentiation and tumorigenesis. In Enwonwu, C. (ed.) Diet, Nutrition and Cancer. Meharry Medical College, Nashville, TN, Vol. IV. pp. 185-201.
24. Moon, R.C., Mehta, R.G. and Rao, K.V.N. (1994) Retinoids and cancer in experimental animals. In Sporn, M.B., Roberts, A.B. and Goodman, D.S. (eds) The Retinoids: Biology, Chemistry and Medicine. Raven Press. New York, NY, pp. 573-595.
25. Kelloff, G.J. (1999) Perspectives on cancer chemoprevention research and drug development. Adv. Cancer Res., 278, 199-334.
26. Kelloff, G.J., Hawk, E.T., Karp, J.E., Crowell, J.A., Boone, C.W., Steele, V.E., Lubet, R.A. and Sigman, C.C. (1997) Progress in clinical chemoprevention. Semin. Oncol., 24, 241-252.
27. Kelloff, G.J., Crowell, J.A., Hawk, E.T., Steele, V.E., Lubet, R.A., Boone, C.W., Covey, J.M., Doody, L.A., Omenn, G.S., Greenwald, P., Hong, W.K., Parkinson, D.R., Bagheri, D., Baxter, G.T., Blunden, M., Doeltz, M.K., Eisenhauer, K.M., Johnson, K., Longfellow, D.G., Knapp, G.G., Malone, W.F., Nayfield, S.G., Seifried, H.E., Swall, L.M. and Sigman, C.C. (1996) Clinical development plan: 9-cis-retinoic acid. J. Cell. Biochem., 26 (suppl.), 158-167.
28. De Luca, L.M. (1978) Historical developments in vitamin A research. In De Luca, H.F. (ed.) Fat Soluble Vitamins. Plenum, New York, NY. pp. 1-67.
29. Kelloff, G.J., Crowell, J.A., Hawk, E.T., Steele, V.E., Lubet, R.A., Boone, C.W., Covey, J.M., Doody, L.A., Omenn, G.S., Greenwald, P., Hong, W.K., Parkinson, D.R., Bagheri, D., Baxter, G.T., Blunden, M., Doeltz, M.K., Eisenhauer, K.M., Johnson, K., Longfellow, D.G., Knapp, G.G., Malone, W.F., Nayfield, S.G., Seifreid, H.E., Swall, L.M. and Sigman, C.C. (1996) Clinical development plan: vitamin A. J. Cell. Biochem., 26 (suppl.), 269-306.
30. Kelloff, G.J., Crowell, J.A., Hawk, E.T., Steele, V.E., Lubet, R.A., Boone, C.W., Covey, J.M., Doody, L.A., Omenn, G.S., Greenwald, P., Hong, W.K., Parkinson, D.R., Bagheri, D., Baxter, G.T., Blunden, M., Doeltz, M.K., Eisenhauer, K.M., Johnson, K., Longfellow, D.G., Knapp, G.G., Malone, W.F., Nayfield, S.G., Seifreid, H.E., Swall, L.M. and Sigman, C.C. (1996) Clinical development plan: 13-cis-retinoic acid. J. Cell. Biochem., 26 (suppl.), 168-201.
31. Chen, L.C. and De Luca, L.M. (1995) Retinoids and skin cancer. In Mukhtar, H. (ed.) Skin Cancer: Mechanisms and Human Relevance. CRC Press, Boca Raton, FL, pp. 401-424.
32. Yuspa, S.H., Kilkenny, A.E., Roop, D.R., Strickland, J.E., Tucker, R., Hennings, H. and Jaken, S. (1989) Consequences of exposure to initiating levels of carcinogens in vitro and in vivo: altered differentiation and growth, mutations and transformation. In Slaga, T.J., Klein-Szanto, A.J.P., Boutwell, R.K., Stevenson, D.E., Spitzer, H.L. and D'Motto, B. (eds) Skin Carcinogenesis: Mechanisms and Human Relevance. Alan R. Liss, New York, NY, pp. 127-135.
33. Chen, L.C., Tarone, R., Huynh, M. and De Luca, L.M. (1995) High dietary retinoic acid inhibits tumor promotion and malignant conversion in a two-stage skin carcinogenesis protocol using 7,12-dimethylbenz(a)-anthracene as the initiator and mezerein as the tumor promoter in female SENCAR mice. Cancer Lett., 95, 113-118.
34. Chen, L.C., Sly, L. and De Luca, L.M. (1994) High dietary retinoic acid prevents malignant conversion of skin papillomas induced by a two-stage carcinogenesis protocol in female SENCAR mice. Carcinogenesis, 15, 2383-2386.
35. Tennenbaum, T., Lowry, D., Darwiche, N., Morgan, D.L., Gartsbein, M., Hansen, L., De Luca, L.M., Hennings, H. and Yuspa, S.H. (1998) Topical retinoic acid reduces skin papilloma formation but resistant papillomas are at high risk for malignant conversion. Cancer Res., 58, 1435-1443.
36. Darwiche, N., Celli, G., Tennenbaum, T., Glick, A.B., Yuspa, S.H. and De Luca, L.M. (1995) Mouse skin tumor progression results in differential expression of retinoic acid and retinoid X receptors. Cancer Res., 55, 2774-2782.
37. Xiao, J.H., Durand, B., Chambon, P. and Voorhees, J.J. (1995) Endogenous retinoic acid receptor (RAR)-retinoid X receptor (RXR) heterodimers are the major functional forms regulating retinoid-responsive elements in adult human keratinocytes. Binding of ligands to RAR only is sufficient for RAR-RXR heterodimers to confer ligand-dependent activation of hRAR β2/ RARE (DR5). J. Biol. Chern., 270, 3001-3011.
38. Ha oncogene and high risk for premalignant progression. Cancer Res., 56, 4942-4959.
39. Lotan, R. (1996) Retinoids and their receptors in modulation of differentiation, development and prevention of head and neck cancers. Anticancer Res., 16, 2415-2419.
40. Lotan, R. (1996) Retinoids in cancer chemoprevention. FASEB J., 10, 1031-1039.
41. Khuri, F.R., Lippman, S.M., Spitz, M.R., Lotan, R. and Hong, W.K. (1997) Molecular epidemiology and retinoid chemoprevention of head and neck cancer. J. Natl Cancer Inst., 89, 199-211.
42. Kelloff, G.J., Crowell, J.A., Boone, C.W., Steele, V.E., Lubet, R.A., Greenwald, P., Alberts, D.S., Covey, J.M., Doody, L.A., Knapp, G.G., Nayfield, S.G., Parkinson, D.R., Prasad, V.K., Prorok, P.C., Sausville, E.A. and Sigman, C.C. (1994) Clinical development plan: N-(4-hydroxyphenyl)retinamide. J. Cell Biochem., 20 (suppl.), 176-196.
43. Moon, R.C. and Constantinou, A.I. (1997) Dietary retinoids andcarotenoids in rodent models of mammary tumorigenesis. Breast Cancer Res. Treat., 46, 181-189.
44. Moon, R.C., Thompson, H.J., Becci, P.J., Grubbs, C.J., Gander, R.J., Newton, D.L., Smith, J.M., Phillips, S.L., Henderson, W.R., Mullen, L.T., Brown, C.C. and Sporn, M.B. (1979) N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res., 39, 1339-1346.
45. Hultin, T.A., May, C.M. and Moon,R.C. (1986) N-(4-hydroxyphenyl)-all-trans-retinamide pharmacokinetics in female rats and mice. Drug Metab. Dispos., 14, 714-717.
46. Mehta, R.G., Hultin, T.A. and Moon, R.C. (1988) Metabolism of the chemopreventive retinoid N-(4-hydroxyphenyl)retinamide by mammary gland in organ culture. Biochem. J., 256, 579-584.
47. Mehta, R.G., Moon, R.C., Hawthorne, M., Formelli, F. and Costa, A. (1991) Distribution of fenretinide in the mammary gland of breast cancer patients. Eur. J. Cancer. 27, 138-141.
48. Veronesi, U., De Palo, G., Marubini, E., Costa, A., Formelli, F., Mariani, L., Decensi, A., Camerini, T., Del Turco, M.R., Di Mauro, M.G., Muraca, M.G., Del Vecchio, M., Pinto, C., D'Aiuto, G., Boni, C., Campa, T., Magni, A., Miceli, R., Perloff, M., Malone, W.F. and Sporn, M.B. (1999) Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer [In Process Citation]. J. Natl Cancer Inst., 91, 1847-1856.
49. Costa, A., Formelli, F., Chiesa, F., Decensi, A., De Palo, G. and Veronesi, U. (1994) Prospects of chemoprevention of human cancers with the synthetic retinoid renretinide. Cancer Res., 54, 2032s-2037s.
50. De Palo, G., Camerini, T., Marubini, E., Costa, A., Formelli, F., Del Vecchio, M., Mariani, L., Miceli, R., Mascotti, G., Magni, A., Campa, T., Di Mauro, M.G., Attili, A., Maltoni, C., Del Turco, M.R., Decensi, A., D'Aiuto, G. and Veronesi, U. (1997) Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual. Tumori, 83, 884-894.
51. McCormick, D.L., Rao, K.V., Steele, V.E., Lubet, R.A., Kelloff, G.J. and Bosland, M.C. (1999) Chemoprevention of rat prostate carcinogenesis by 9-cis-retinoic acid. Cancer Res., 59, 521-524.
52. Moon, R.C. (1994) Vitamin A, retinoids and breast cancer. Adv. Exp. Med. Biol., 364, 101-107.
53. Gottardis, M.M., Bischoff, E.D., Shirley, M.A., Wagoner, M.A., Lamph, W. W. and Heyman, R.A. (1996) Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res., 56, 5566-5570.
54. Boehm, M.F., Zhang, L., Zhi, L., McClurg, M.R., Berger, E., Wagoner, M., Mais, D.E., Suto, C.M., Davies, J.A. and Heyman, R.A. (1995) Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J. Med. Chem., 38, 3146-3155.
55. Anzano, M.A., Byers, S.W., Smith, J.M., Peer, C.W., Mullen, L.T., Brown, C.C., Roberts, A.B. and Sporn, M.B. (1994) Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res., 54, 4614-4617.
56. Bischoff, E.D., Gottardis, M.M., Moon, T.E., Heyman, R.A. and Lamph, W.W. (1998) Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res., 58, 479-484.
57. Moon, R.C. and Mehta, R.G. (1982) Retinoid binding in normal and neoplastic mammary tissue. In Leavitt, W.W. (ed.) Hormones and Cancer. Plenum Press, New York, NY, pp. 231-249.
58. McCormick, D.L., Mehta, R.G., Thompson, C.A., Dinger, N., Caldwell, J.A. and Moon, R.C. (1982) Enhanced inhibition of mammary carcinogenesis by combined treatment with N-(4-hydroxyphenyl)retinamide and ovariectomy. Cancer Res., 42, 508-512.
59. Ratko, T.A., Detrisac, C.J., Dinger, N.M., Thomas, C.F., Kelloff, G.J. and Moon, R.C. (1989) Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res., 49, 4472-4476.
60. Anzano, M.A., Peer, C.W., Smith, J.M., Mullen, L.T., Shrader, M.W., Logsdon, D.L., Driver, C.L., Brown, C.C., Roberts, A.B. and Sporn, M.B. (1996) Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J. Natl Cancer Inst., 88, 123-125.
61. Hong, W.K. and Sporn, M.B. (1997) Recent advances in chemoprevention of cancer. Science, 278, 1073-1077.
62. Gilbert, R.D., Karabus, C.D. and Mills, A.E. (1987) Acute promyelocytic leukemia. A childhood cluster. Cancer, 59, 933-935.
63. Grignani, F., Fagioli, M., Alcalay, M., Longo, L., Pandolfi, P.P., Donti, E., Biondi, A., Lo Coco, F. and Pelicci, P.G. (1994) Acute promyelocytic leukemia: from genetics to treatment. Blood, 83, 10-25.
64. Chen, Z., Brand, N.J., Chen, A., Chen, S.J., Tong, J.H., Wang, Z.Y., Waxman, S. and Zelent, A. (1993) Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11; 17) translocation associated with acute promyelocytic leukaemia. EMBO J., 12, 1161-1167.
65. Warrell, R.P. Jr (1996) Pathogenesis and management of acute promyelocytic leukemia. Annu. Rev. Med., 47, 555-565.
66. Vyas, R.C., Frankel, S.R., Agbor, P., Miller, W.H. Jr, Warrell, R.P. Jr and Hittelman, W.N. (1996) Probing the pathobiology of response to all-trans retinoic acid in acute promyelocytic leukemia: premature chromosome condensation/fluorescence in situ hybridization analysis. Blood, 87, 218-226.
67. Huang, M.E., Ye, Y.C., Chen, S.R., Chai, J.R., Lu, J.X., Zhoa, L., Gu, L.J. and Wang, Z.Y. (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood, 72, 567-572.
68. Lo Coco, F., Nervi, C., Avvisati, G. and Mandelli, F. (1998) Acute promyelocytic leukemia: a curable disease. Leukemia, 12, 1866-1880.
69. Miller, W.H. Jr, Kakizuka, A., Frankel, S.R., Warrell, R.P. Jr, DeBlasio, A., Levine, K., Evans, R.M. and Dmitrovsky, E. (1992) Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc. Natl Acad. Sci. USA, 89, 2694-2698.
70. Wells, R.A., Catzavelos, C. and Kamel-Reid, S. (1997) Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nature Genet., 17, 109-113.
71. Redner, R.L., Rush, E.A., Faas, S., Rudert, W.A. and Corey, S.J. (1996) The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood, 87, 882-886.
72. Licht, J.D., Chomienne, C., Goy, A., Chen, A., Scott, A.A., Head, D.R., Michaux, J.L., Wu, Y., DeBlasio, A. and Miller, W.H. Jr (1995) Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood, 85, 1083-1094.
73. Brown, D., Kogan, S., Lagasse, E., Weissman, I., Alcalay, M., Pelicci, P.G., Atwater, S. and Bishop, J.M. (1997) A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc. Natl Acad. Sci. USA, 94, 2551-2556.
74. Grisolano, J.L., Wesselschmidt, R.L., Pelicci, P.G. and Ley, T.J. (1997) Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood, 89, 376-387.
75. Altabef, M., Garcia, M., Lavau, C., Bae, S.C., Dejean, A. and Samarut, J. (1996) A retrovirus carrying the promyelocyte-retinoic acid receptor PML-RARα fusion gene transforms haematopoietic progenitors in vitro and induces acute leukaemias. EMBO J., 15, 2707-2716.
76. Leid, M., Kastner, P. and Chambon, P. (1992) Multiplicity generates diversity in the retinoic acid signalling pathways. Trends Biochem. Sci., 17, 427-433.
77. Kamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss,B., Lin, S.C., Heyman, R.A., Rose, D.W., Glass, C.K. and Rosenfeld, M.G. (1996) A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell, 85, 403-414.
78. Muller, S., Matunis, M.J. and Dejean, A. (1998) Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J., 17, 61-70.
79. Sternsdorf, T., Jensen, K. and Will, H. (1997) Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PICI/SUMO-1. J. Cell Biol., 139, 1621-1634.
80. Kelly, C., Van Driel, R. and Wilkinson, G.W.G. (1996) Disruption of PML-associated nuclear bodies during human cytomegalovirus infection. J. Gen. Virol., 76, 2887-2893.
81. Doucas, V., Ishov, A.M., Romo, A., Juguilon, H., Weitzman, M.D., Evans, R.M. and Maul, G.G. (1996) Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure. Genes Dev., 10, 196-207.
82. Everett, R.D. and Maul, G.G. (1994) HSV-1 IE protein Vmw110 causes redistribution of PML. EMBO J., 13, 5062-5069.
83. Carvalho, T., Seeler, J.S., Ohman, K., Jordan, P., Pettersson, U., Akusjarvi, G., Carmo-Fonseca, M. and Dejean, A. (1995) Targeting of adenovirus E1A and E4-ORF3 proteins to nuclear matrix-associated PML bodies. J. Cell Biol., 131, 45-56.
84. Le, X.-F., Vallian, S., Mu, Z.-M., Hung, M.-C. and Chang, K.-S. (1998) Recombinant PML adenovirus suppresses growth and tumorigenicity of human breast cancer cells by inducing G1 cell cycle arrest and apoptosis. Oncogene, 16, 1839-1849.
85. HE, C., Wilhelm, S.M., Pentland, A.P., Marmer, B.L., Grant, G.A., Eisen, A.Z. and Goldberg, G.I. (1989) Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc. Natl Acad. Sci. USA, 86, 2632-2636.
86. Quignon, F., De Bels, F., Koken, M., Feunteun, J., Ameisen, J.C. and de The, H. (1998) PML induces a novel caspase-independent death process. Nature Genet., 20, 259-265.
87. Wang, Z.G., Ruggero, D., Ronchetti, S., Zhong, S., Gaboli, M., Rivi, R. and Pandolfi, P.P. (1998) PML is essential for multiple apoptotic pathways. Nature Genet., 20, 266-272.
88. Vallian, S., Gaken, J.A., Gingold, E.B., Kouzarides, T., Chang, K.S. and Farzaneh, F. (1998) Modulation of Fos-mediated AP-1 transcription by the promyelocytic leukemia protein. Oncogene, 16, 2843-2853.
89. Wang, Z.G., Delva, L., Gaboli, M., Rivi, R., Giorgio, M., Cordon-Cardo, C., Grosveld, F. and Pandolfi, P.P. (1998) Role of PML in cell growth and the retinoic acid pathway. Science, 279, 1547-1551.
90. Weis, K., Rambaud, S., Lavau, C., Jansen, J., Carvalho, T., Carmo-Fonseca, M., Lamond, A. and Dejean, A. (1994) Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell, 76, 345-356.
91. Lin, R.J., Nagy, L., Inoue, S., Shao, W., Miller, W.H. Jr and Evans, R.M. (1998) Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature, 391, 811-814.
92. Grignani, F., De Matteis, S., Nervi, C., Tomassoni, L., Gelmetti, V., Cioce, M., Fanelli, M., Ruthardt, M., Ferrara, F.F., Zamir, I., Seiser, C., Lazar, M.A., Minucci, S. and Pelicci, P.G. (1998) Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature, 391, 815-818.
93. Kakizuka, A., Miller, W.H. Jr, Umesono, K., Warrell, R.P. Jr, Frankel, S.R., Murty, V.V., Dmitrovsky, E. and Evans, R.M. (1991) Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell, 66, 663-674.
94. Kastner, P., Perez, A., Lutz, Y., Rochette-Egly, C., Gaub, M.P., Durand, B., Lanotte, M., Berger, R. and Chambon, P. (1992) Structure, localization and transcriptional properties of two classes of retinoic acid receptor α fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins. EMBO J., 11, 629-642.
95. Nason-Burchenal, K., Takle, G., Pace, U., Flynn, S., Allopenna, J., Martin, P., George, S.T., Goldberg, A.R. and Dmitrovsky, E. (1998) Targeting the PML/ RAR alpha translocation product triggers apoptosis in promyelocytic leukemia cells. Oncogene, 17, 1759-1768.
96. Warrell, R.P. Jr, de The, H., Wang, Z.Y. and Degos, L. (1993) Acute promyelocytic leukemia. N. Engl. J. Med., 329, 177-189.
97. Degos, L., Dombret, H., Chomienne, C., Daniel, M.T., Miclea, J.M., Chastang, C., Castaigne, S. and Fenaux, P. (1995) All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia [see comments]. Blood, 85, 2643-2653.
98. Chen, Z.X., Xue, Y.Q., Zhang, R., Tao, R.F., Xia, X.M., Li, C., Wang, W., Zu, W.Y., Yao, X.Z. and Ling, B.J. (1991) A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood, 78, 1413-1419.
99. Shao, W., Fanelli, M., Ferrara, F.F., Riccioni, R., Rosenauer, A., Davison, K., Lamph, W.W., Waxman, S., Pelicci, P.G., Lo Coco, F., Avvisati, G., Testa, U., Peschle, C., Gambacorti-Passerini, C., Nervi, C. and Miller, W.H. Jr (1998) Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J. Natl Cancer Inst., 90, 124-133.
100. Soignet, S.L., Maslak, P., Wang, Z.G., Jhanwar, S., Calleja, E., Dardashti, L.J., Corso, D., DeBlasio, A., Gabrilove, J., Scheinberg, D.A., Pandolfi, P.P. and Warrell, R.P. Jr (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide [see comments]. N. Engl. J. Med., 339, 1341-1348.
101. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 89, 3354-3360.
102. Zhu, J., Koken, M.H., Quignon, F., Chelbi-Alix, M.K., Degos, L., Wang, Z.Y., Chen, Z. and de The, H. (1997) Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc. Natl Acad. Sci. USA, 94, 3978-3983.
103. Wang, Z.G., Rivi, R., Delva, L., Konig, A., Scheinberg, D.A., Gambacorti-Passerini, C., Gabrilove, J.L., Warrell, R.P. Jr and Pandolfi, P.P. (1998) Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood, 92, 1497-1504.
104. Warrell, R.P. Jr. He, L.Z., Richon, V., Calleja, E. and Pandolfi, P.P. (1998) Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl Cancer Inst., 90, 1621-1625.
105. Petkovich, M., Brand, N.J., Krust, A. and Chambon, P. (1987) A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature, 330, 444-450.
106. Giguere, V., Ong, E.S., Segui, P. and Evans, R.M. (1987) Identification of a receptor for the morphogen retinoic acid. Nature, 330, 624-629.
107. Sommer, A., Tarwotjo, I., Djunaedi, E., West, K.P. Jr and Loeden, A.A. (1986) Impact of vitamin A supplementation on childhood mortality: a randomized controlled community trial. Lancet, i, 1169-1173.
108. De Luca, L.M., Darwiche, N., Jones, C.S. and Scita, G. (1995) Retinoids in differentiation and neoplasia. Scient. Am. Sci. Med., 2, 28-37.
109. Kumar, R., Shoemaker, A.R. and Verma, A.K. (1994) Retinoic acid nuclear receptors and tumor promotion: decreased expression of retinoic acid nuclear receptors by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate. Carcinogenesis, 15, 701-705.
110. Xu, X.C., Sozzi, G., Lee, J.S., Lee, J.J., Pastorino, U., Pilotti, S., Kurie, J.M., Hong, W.K. and Lotan, R. (1997) Suppression of retinoic acid receptor β in non-small-cell lung cancer in vivo: implications for lung cancer development. J. Natl Cancer Inst., 89, 624-629.
111. Xu, X.C., Mitchell, M.F., Silva, E., Jetten, A. and Lotan, R. (1999) Decreased expression of retinoic acid receptors, transforming growth factor beta, involucrin and cornifin in cervical intraepithelial neoplasia. Clin. Cancer Res., 5, 1503-1508.
112. Lotan, R., Xu, X.C., Lippman, S.M., Ro, J.Y., Lee, J.S., Lee, J.J. and Hong, W.K. (1995) Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N. Engl. J. Med., 332, 1405-1410.
113. Giandomenico, V., Andreola, F., de la Concepcion, M.L., Collins, S.J. and De Luca, L.M. (1999) Retinoic acid and 4-hydroxyphenylretinamide induce growth inhibition and tissue transglutaminase through different signal transduction pathways in mouse fibroblasts (NIH 3T3 cells). Carcinogenesis, 20, 1133-1135.
114. Freyne, E., Raeymaekers, A., Venet, M., Sanz, G., Wouters, W., De Coster, R. and Wauwe, J.V. (1998) Synthesis of LIAZAL, a retinoic acid metabolism blocking agent (RAMBA) with potential clinical applications in oncology and dermatology. Bioorg. Med. Chem. Lett., 8, 267-272.
115. Mulshine, J.L., De Luca, L.M. and Dedrick, R.L. (1998) Regional delivery of retinoids: a new approach to early lung cancer intervention. In Martinet, Y., Hirsch, F.R., Martinet, N. and Vignaud, J.M. (eds) Clinical and Biological Basis of Lung Cancer Prevention. Birkhauser Verlag Ag, Basel, Switzerland, Vol. 24, pp. 273-283.
116. Hozumi, M. (1998) Differentiation therapy of leukemia: achievements, limitations and future prospects. Int. J. Hematol., 68, 107-129.